UroGen Pharma Ownership
| URGN Stock | USD 11.66 0.13 1.13% |
Shares in Circulation | First Issued 2014-12-31 | Previous Quarter 43.1 M | Current Value 42.9 M | Avarage Shares Outstanding 20 M | Quarterly Volatility 9.9 M |
UroGen |
UroGen Stock Ownership Analysis
About 87.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 239.57. UroGen Pharma recorded a loss per share of 2.96. The entity had not issued any dividends in recent years. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Urogen Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 201 people. For more information please call Elizabeth Barrett at 646 768 9780 or visit https://www.urogen.com.Besides selling stocks to institutional investors, UroGen Pharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different UroGen Pharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align UroGen Pharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
UroGen Pharma Quarterly Liabilities And Stockholders Equity |
|
UroGen Pharma Insider Trades History
About 8.0% of UroGen Pharma are currently held by insiders. Unlike UroGen Pharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against UroGen Pharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of UroGen Pharma's insider trades
UroGen Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as UroGen Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading UroGen Pharma backward and forwards among themselves. UroGen Pharma's institutional investor refers to the entity that pools money to purchase UroGen Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Diadema Partners Lp | 2024-12-31 | 50 K | Llbh Private Wealth Management, Llc | 2024-12-31 | 39 K | Alps Advisors Inc | 2024-12-31 | 34.1 K | Tidal Investments Llc. | 2024-12-31 | 30.5 K | Jpmorgan Chase & Co | 2024-12-31 | 21.1 K | Vivaldi Capital Management, Llc | 2024-12-31 | 20.1 K | Susquehanna Fundamental Investments, Llc | 2024-12-31 | 19.5 K | Legal & General Group Plc | 2024-09-30 | 15.9 K | Aquatic Capital Management Llc | 2024-12-31 | 9.4 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.2 M | Vestal Point Capital Lp | 2024-12-31 | 1.6 M |
UroGen Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific UroGen Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on UroGen Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases UroGen Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
UroGen Pharma Outstanding Bonds
UroGen Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. UroGen Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most UroGen bonds can be classified according to their maturity, which is the date when UroGen Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
UroGen Pharma Corporate Filings
| 17th of March 2025 Other Reports | ViewVerify | |
8K | 10th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 18th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth 0.044 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.